| Diabetes Mellitus, Non-Insulin-Dependent
Lyumjev vs Synjardy
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Lyumjev vs Synjardy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSynjardy has a higher rate of injection site reactions vs Lyumjev based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Synjardy but not Lyumjev, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lyumjev
Synjardy
At A Glance
SC injection
With each meal
Rapid-acting insulin analog
Oral
Once or twice daily
SGLT2 inhibitor / biguanide
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
- Congestive heart failure
- Chronic Kidney Diseases
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Administer U-100 or U-200 SC at meal start or within 20 minutes after starting a meal into abdomen, upper arm, thigh, or buttocks; U-100 also available via CSII insulin pump or IV infusion (under medical supervision, diluted to 1 unit/mL); individualize dose based on metabolic needs and glucose monitoring.
Diabetes Mellitus, Non-Insulin-Dependent SYNJARDY: empagliflozin 10 mg/day (may increase to 25 mg/day) plus metformin HCl up to 2,000 mg/day, taken orally twice daily with meals; SYNJARDY XR: once daily with morning meal; not recommended if eGFR <45 mL/min/1.73 m2.
Cardiovascular Diseases, Congestive heart failure, Chronic Kidney Diseases Empagliflozin 10 mg/day component as part of SYNJARDY or SYNJARDY XR, taken orally; not recommended if eGFR <45 mL/min/1.73 m2.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin lispro-aabc or any excipient in LYUMJEV
- Severe renal impairment (eGFR <30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to empagliflozin, metformin HCl, or any excipient in SYNJARDY or SYNJARDY XR
Adverse Reactions
Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, infusion site reaction, infusion site pain
Serious Hypoglycemia (including severe), severe hypersensitivity reactions (anaphylaxis, angioedema, bronchospasm, hypotension, shock)
Postmarketing Localized cutaneous amyloidosis at injection site, hyperglycemia or hypoglycemia associated with injection into areas of localized cutaneous amyloidosis
Most common (>=5%) Hypoglycemia (with sulfonylurea), urinary tract infection, nasopharyngitis, diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache
Serious Lactic acidosis, diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), hypersensitivity reactions, vitamin B12 deficiency, lower limb amputation
Postmarketing Constipation, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, angioedema, rash, urticaria, cholestatic/hepatocellular liver injury
Pharmacology
Rapid-acting human insulin analog that binds insulin receptors to stimulate peripheral glucose uptake in skeletal muscle and fat and inhibit hepatic glucose production, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.
Empagliflozin is an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion; metformin HCl is a biguanide antihyperglycemic agent that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lyumjev
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (8/12)
Synjardy
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Lyumjev
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Synjardy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Lyumjev
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Synjardy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Lyumjev.
No savings programs available for Synjardy.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LyumjevView full Lyumjev profile
SynjardyView full Synjardy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.